A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors

Src is overexpressed in various cancers, including 27% of non-small cell lung cancer NSCLC, and is correlated with poor clinical outcomes. We hypothesize that Src kinase inhibitors, including Bosutinib, may exhibit clinical synergy in combination with the antifolate drug pemetrexed. In this Phase I,...

Descripción completa

Detalles Bibliográficos
Autores principales: Karim, Nagla Abdel, Ullah, Asad, Wang, Hongkun, Shoukier, Mahran, Pulliam, Steven, Khaled, Ahmed, Patel, Nikhil, Morris, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776616/
https://www.ncbi.nlm.nih.gov/pubmed/36547158
http://dx.doi.org/10.3390/curroncol29120744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776616/
https://www.ncbi.nlm.nih.gov/pubmed/36547158
http://dx.doi.org/10.3390/curroncol29120744

Ejemplares similares